1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Paxman AB (publ)

Paxman AB (publ)

PXMBF
Paxman AB (publ)US flagOther OTC
3.50
USD
- -
- -
149.87MMarket Cap
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.64
3.62
5.33
4.87
5.51
7.67
11.05
13.31
- -
14.77
Basic EPS, GAAP
-0.57
-0.44
0.17
-1.2
-0.73
-0.54
0.44
2.11
- -
-0.47
Free Cash Flow per Basic Share
-1.65
-1.14
-1.09
-0.92
-1.6
-1.74
-0.51
0.81
- -
-1.02
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.78
0.56
1.17
-0.2
0.36
0.46
1.44
3.11
- -
- -
Tangible Book Value per Share
1.95
0.97
1
-0.1
6.26
4.81
4.65
6.58
- -
9.59
Basic Weighted Avg Shares
12
16
16
16
17
19
19
19
- -
23
Sales/Revenue/Turnover
31
58
85
78
96
146
210
253
313
336
Operating Margin (%)
-21.69
-8.24
-6.99
-14.98
-11
-0.85
6.01
13.24
1.36
-0.39
Depreciation Expense
2
5
8
11
13
17
19
16
24
30
Net Income, GAAP
-7
-7
3
-19
-13
-10
8
40
-17
-11
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
3.14
- -
- -
Profit Margin (%)
-21.46
-12.24
3.23
-24.58
-13.28
-7.08
3.96
15.89
-5.33
-3.2
Working Capital
13
-8
-10
-20
74
42
44
75
167
176
LT Debt
- -
- -
14
16
6
4
3
1
3
4
Total Equity
33
25
28
11
126
114
123
164
405
409
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
20.56
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
72.21
- -
- -
Return on Common Equity (%)
- -
-78.04
19.91
- -
- -
-138.35
46.24
92.89
-50.83
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
7
10
1
LT Borrowings
3
3
4
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
23
23
23
Market Capitalization
683
703
756

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
235
223
226
Cash, Cash Equivalents & STI
130
121
106
Accounts Receivable, Net
72
46
81
Inventories
30
33
37
Total Current Liabilities
50
56
50
Payables & Accruals
- -
- -
- -
ST Debt
7
10
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
246.77%
147.06%
Free Cash Flow
- -
-85.4%
-204.46%
Net Income, GAAP
- -
1.54%
-141.58%
Sales/Revenue/Turnover
- -
32.64%
23.85%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
59
63
65
66
253
2025
67
75
87
84
313
2026
90
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.69
0.52
0.26
0.64
2.11
2025
-0.29
-0.14
0.06
-0.38
- -
2026
-0.01
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Richard Paxman
Full Time Employees
105
Sector
Healthcare
Industry
Medical - Devices
Address
Pirgatan 13 Karlshamn Sweden 374 35
IPO Date
Apr 23, 2019
Website
paxmanscalpcooling.com
Similar Companies
Second Sight Medical Products Inc (EYESW)
SomnoMed Limited (SOM.AX)
Zylox-Tonbridge Medical Technology Co., Ltd. (2190.HK)
Rapid Therapeutic Science Laboratories, Inc. (RTSL)
Broncus Holding Corporation (2216.HK)
Oventus Medical Limited (OVN.AX)
Business
Paxman AB (publ) (Ticker: PXMBF) develops, manufactures, and commercializes scalp cooling technology to prevent hair loss (alopecia) in patients undergoing chemotherapy treatment for cancer. The company's core product is the Paxman Scalp Cooling System, a medical device featuring the Paxman Plus and Paxman Orbis models; these systems utilize advanced thermoelectric cooling technology to maintain scalp temperatures between 10-18°C during chemotherapy infusions, thereby reducing chemotherapy-induced alopecia by constricting blood vessels and minimizing drug delivery to hair follicles. Paxman offers related services including clinical training, device maintenance, and patient support programs; the systems are compatible with various chemotherapy regimens for breast, ovarian, colorectal, and other cancers, and are available for sale, rental, or lease to hospitals, oncology clinics, and cancer centers. Founded in 1998 and headquartered in Rotherham, United Kingdom, Paxman operates globally with sales and distribution in Europe, North America, Asia-Pacific, and other regions, targeting healthcare providers serving adult and pediatric cancer patients. In recent developments, Paxman strengthened its U.S. market presence through expanded partnerships with leading oncology networks and secured regulatory approvals for enhanced device features; the company also announced a strategic funding round in 2024 to support R&D for next-generation portable scalp cooling solutions and entered a distribution alliance in Asia, marking significant operational expansions within the last two years.